Storia in 3 fonti

FDA extends review of Capricor cell therapy; Pain drug startup to go public

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.

Raccontata da

biopharmadive.com

endpoints.news

benzinga.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo2 g fa

FDA extends review of Capricor cell therapy; Pain drug startup to go public

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.

originale

benzinga.com1 g fa

Why Is Capricor Therapeutics Stock Trading Higher on Monday? - Capricor Therapeutics (NASDAQ:CAPR)

Capricor stock rises as FDA extends its deramiocel review to Nov. 22 following new Phase 3 HOPE-3 data and an advisory panel setback.

Leggi questa versione → originale

FDA extends review of Capricor cell therapy; Pain drug startup to go public

Confronto fonti

FDA extends review of Capricor cell therapy; Pain drug startup to go public

Why Is Capricor Therapeutics Stock Trading Higher on Monday? - Capricor Therapeutics (NASDAQ:CAPR)

Timeline cronologica

Shareholder pressures Capricor; Lilly dives deeper into vaccines

FDA extends review of Capricor cell therapy; Pain drug startup to go public

Capricor's Duchenne cell therapy gets PDUFA date extended as FDA reviews new data

Capricor's Duchenne cell therapy gets PDUFA date extended as FDA reviews new data

Why Is Capricor Therapeutics Stock Trading Higher on Monday? - Capricor Therapeutics (NASDAQ:CAPR)